NEUROECTODERMAL/NOREPINEPHRINE STUDY

I-131-MIBG

INDICATIONS:

Identification and localization of tumors of neuroectodermal tissues:

1. Benign and malignant pheochromocytomas.
2. Neuroblastomas.
3. Carcinoid tumors.
4. Medullary thyroid tumors.
5. Paragangliomas.
6. Chemodectomas.

RADIOPHARMACEUTICAL:

I-131-metaiodobenzylguanidine (I-131-MIBG). Dose: 500-800 µCi I.V.

PATIENT PREPARATION:

Drugs to be avoided prior to study:

1. Labetalol.
2. Reserpine.
3. Tricyclic antidepressants.
4. Sympathomimetics.
5. Calcium-channel blockers.

Patient will be given Lugal's Solution during the test to protect the thyroid gland.

SCANNING TIME:

Initially: 15 minutes for injection.

Delayed images at 48 hours: 1 hour for standard planar images. (Additional delayed images may be necessary.)

1 drop of saturated solution of potassium iodide is given orally 3 times a day, for a total of 5 days, beginning the day before injection of the radiopharmaceutical.